Scarica l'app Stockscreener
0.6522
10.47%
-0.0763
Precedente Chiudi:
$0.7285
Aprire:
$0.69
Volume 24 ore:
375.36K
Relative Volume:
0.11
Capitalizzazione di mercato:
$3.13M
Reddito:
-
Utile/perdita netta:
$-21.33M
Rapporto P/E:
-0.00573
EPS:
-113.7479
Flusso di cassa netto:
$-9.12M
1 W Prestazione:
-0.41%
1M Prestazione:
+25.91%
6M Prestazione:
-37.90%
1 anno Prestazione:
-86.63%
Intervallo 1D:
$0.647
$0.71
Intervallo di 1 settimana:
$0.61
$0.80
Portata 52W:
$0.4728
$6.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Nome
Zyversa Therapeutics Inc
Settore
Industria
Telefono
908-370-5102
Indirizzo
217 W. MAIN STREET, SOMERVILLE
Confronta ZVSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.6522 | 3.13M | 0 | -21.33M | -9.12M | -113.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc Borsa (ZVSA) Ultime notizie
ZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded at Wall Street Zen - Defense World
ZyVersa Therapeutics Stockholders Approve Key Proposals - TipRanks
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
At $0.65 Price, ZyVersa Therapeutics Inc (ZVSA) Is Sitting And Waiting - Stocksregister
ZyVersa Therapeutics Reports Q1 2025 Financial Results - TipRanks
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
ZVSA: ZyVersa Therapeutics' IC 100 Shows Promise in PD Treatment - GuruFocus
ZyVersa’s IC 100 shows promise in Parkinson’s treatment By Investing.com - Investing.com India
ZyVersa Therapeutics highlights publication of data on IC 100 - TipRanks
ZyVersa’s IC 100 shows promise in Parkinson’s treatment - Investing.com Australia
ZyVersa Therapeutics Highlights Published Study Reinforcing - GlobeNewswire
Breakthrough Study Reveals Key to Fighting Parkinson's: ZyVersa's Novel Drug Shows Promise in $13B Market - Stock Titan
ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India
ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire
ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks
ZyVersa progresses with obesity inflammation treatment - Investing.com Australia
ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan
ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com
ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com
Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus
Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq
ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire
Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
Zyversa Therapeutics Inc Azioni (ZVSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):